Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy  

作　　者：Haidong Tang Mingzhao Zhu Jian Qiao Yang-Xin Fu 

机构地区：[1]Department of Pathology,University of Texas,Southwestern Medical Center,Dallas,TX 75235,USA [2]IBP-UTSW Joint Immunotherapy Group,Chinese Academy of Science,Key Laboratory for Infection and Immunity,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China

出　　处：《Cellular & Molecular Immunology》2017年第10期809-818,共10页中国免疫学杂志（英文版）

基　　金：by the US National Institutes of Health through National Cancer Institute grants CA141975 and CA97296,CPRIT grant RR150072,grants from the Chinese Academy of Sciences(XDA09030303);grants from the Chinese Ministry of Science and Technology(2012ZX10002006,2011DFA31250 and 2012AA020701)to YXF and a Cancer Resarch Institute Irvington Fellowship to HT.

摘　　要：Tertiary lymphoid structures(TLS)often develop at sites of persistent inflammation,including cancers and autoimmune diseases.In most cases,the presence of TLS correlates with active immune responses.Because of their proximity to pathological loci,TLS are an intriguing target for the manipulation of immune responses.For several years,it has become clear that lymphotoxin(LT)signalling plays critical roles in lymphoid tissue organogenesis and maintenance.In the current review,we will discuss the role of LT signalling in the development of TLS.With a focus on cancers and autoimmune diseases,we will highlight the correlations between TLS and disease progression.We will also discuss the current efforts and potential directions for manipulating TLS for immunotherapies.

关 键 词：autoimmune disease CANCER IMMUNOTHERAPY lymphotoxin signalling tertiary lymphoid structure 

分 类 号：R73[医药卫生—肿瘤]